Immix Biopharma reports Q3 net loss of $13.9 million
IMMX•Immix Biopharma reported a third-quarter 2026 net loss of $13.9 million and operating expenses of $15.9 million. Cash, cash equivalents and marketable securities totaled $340.9 million at September 30, which the company expects to fund operations into mid-2028.
1. Quarterly results
Immix Biopharma reported a third-quarter 2026 net loss of $13.9 million and operating expenses of $15.9 million. Cash, cash equivalents and marketable securities rose 46% from June 30 to $340.9 million at September 30; the company expects the balance to provide operating runway into mid-2028.
2. NXC-201 program
NXC-201 achieved an 89% complete response rate across 45 patients in the NEXICART-2 trial. Immix plans a BLA submission for mid-2027 and expects the NEXICART-3 frontline trial to begin in the first half of 2027.
